Drugs / NLM-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04827953 | Sep 2021 → Apr 2025 overdue | pancreatic ductal adenocarcinoma | Nelum Corp | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07578337 | Jul 2026 → Feb 2029 expected | pancreatic neoplasm | Nelum Corp | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NLM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04827953 ↗ |
| Action | Inhibit | “a Hedgehog pathway inhibitor (NLM-001)” NCT04827953 ↗ |
| Route | Oral | “NLM-001: 800 mg/day, p.o, once daily (4 tablets of 200 mg) days -4 to -1 and 10-13 of each cycle.” NCT07578337 ↗ |